Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprises of various intra-articular and hyaluronic acid injections, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise ultrasonic products offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; bone graft substitutes, a portfolio includes various products that facilitate optimal bone fusion. The company's product includes, nexus, an ultrasonic surgical system, an ultrasonic surgical platform; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite, a handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies, which includes minimally invasive fracture treatments and rehabilitation products. Its products include Exogen, an ultrasound bone stimulation system; and Talisman pulse generator and receiver for peripheral nerve stimulation. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

Bioventus Inc.

An update from Bravura Solutions Limited ( ($AU:BVS) ) is now available. Bravura Solutions Limited has announced a change in the director’s interes...

Current Quarter	$NA	Next Quarter	$NA
Current Year	$0.26	Next Year	$0.49
QoQ Growth	NaN%	YoY Growth	+88.5%
3Y EPS CAGR	-90.7%	Target Price	$15.00
Consensus	Buy	Upside	+98.7%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BVS	$7.55	+1.75%	215.57K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BVS	$7.55	+1.8%	215.57K
3
4
5
6

BVS

BVS

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Bioventus Inc. Data in Excel

Get Bioventus Inc. Data in Excel